These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 21274712)

  • 1. In situ RHAMM protein expression in acute myeloid leukemia blasts suggests poor overall survival.
    Tzankov A; Strasser U; Dirnhofer S; Menter T; Arber C; Jotterand M; Rovo A; Tichelli A; Stauder R; Günthert U
    Ann Hematol; 2011 Aug; 90(8):901-9. PubMed ID: 21274712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RHAMM, p21 combined phenotype identifies microsatellite instability-high colorectal cancers with a highly adverse prognosis.
    Zlobec I; Baker K; Terracciano LM; Lugli A
    Clin Cancer Res; 2008 Jun; 14(12):3798-806. PubMed ID: 18559599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
    Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
    Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of pSTAT5 predicts FLT3 internal tandem duplications in acute myeloid leukemia.
    Obermann EC; Arber C; Jotterand M; Tichelli A; Hirschmann P; Tzankov A
    Ann Hematol; 2010 Jul; 89(7):663-9. PubMed ID: 20066533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules.
    Schmitt M; Li L; Giannopoulos K; Chen J; Brunner C; Barth T; Schmitt A; Wiesneth M; Döhner K; Döhner H; Greiner J
    Exp Hematol; 2006 Dec; 34(12):1709-19. PubMed ID: 17157168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multivariate analyses of prognostic factors in acute myeloid leukemia: relevance of cytogenetic abnormalities and CD34 expression.
    Junghanss C; Waak M; Knopp A; Kleine HD; Kundt G; Leithäuser M; Hilgendorf I; Wolff D; Casper J; Freund M
    Neoplasma; 2005; 52(5):402-10. PubMed ID: 16151585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
    Graf M; Hecht K; Reif S; Pelka-Fleischer R; Pfister K; Schmetzer H
    Eur J Haematol; 2004 Feb; 72(2):89-106. PubMed ID: 14962246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor for hyaluronic acid-mediated motility (RHAMM, CD168) expression is prognostically important in both nodal negative and nodal positive large cell lung cancer.
    Augustin F; Fiegl M; Schmid T; Pomme G; Sterlacci W; Tzankov A
    J Clin Pathol; 2015 May; 68(5):368-73. PubMed ID: 25731190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of MAC-1 (CD11b) in acute myeloid leukemia (AML) is associated with an unfavorable prognosis.
    Graf M; Reif S; Kröll T; Hecht K; Nuessler V; Schmetzer H
    Am J Hematol; 2006 Apr; 81(4):227-35. PubMed ID: 16550517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA-G expression is irrelevant to prognosis in patients with acute myeloid leukemia.
    Guo QY; Chen BG; Ruan YY; Lin A; Yan WH
    Leuk Res; 2011 Oct; 35(10):1350-4. PubMed ID: 21696824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shedding of the endothelial receptor tyrosine kinase Tie2 correlates with leukemic blast burden and outcome after allogeneic hematopoietic stem cell transplantation for AML.
    Koenecke C; Kümpers P; Lukasz A; Dammann E; Verhagen W; Göhring G; Buchholz S; Krauter J; Eder M; Schlegelberger B; Ganser A
    Ann Hematol; 2010 May; 89(5):459-67. PubMed ID: 20054548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens.
    Greiner J; Döhner H; Schmitt M
    Haematologica; 2006 Dec; 91(12):1653-61. PubMed ID: 17145602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
    Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
    J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic factor analysis of 77 old patients with acute myelogenous leukemia].
    Shao B; Gao YR; Wang C; Yan SK; Cai Q; Jiang JL; Yang J; Bai HT; Zhao M; Zhao CX
    Ai Zheng; 2006 Aug; 25(8):1007-12. PubMed ID: 16965684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
    Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
    J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated AF1q expression is a poor prognostic marker for adult acute myeloid leukemia patients with normal cytogenetics.
    Strunk CJ; Platzbecker U; Thiede C; Schaich M; Illmer T; Kang Z; Leahy P; Li C; Xie X; Laughlin MJ; Lazarus HM; Gerson SL; Bunting KD; Ehninger G; Tse W
    Am J Hematol; 2009 May; 84(5):308-9. PubMed ID: 19396856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
    Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia.
    Hussein K; Jahagirdar B; Gupta P; Burns L; Larsen K; Weisdorf D
    Am J Hematol; 2008 Jun; 83(6):446-50. PubMed ID: 18247382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results.
    Ferrara F; Izzo T; Criscuolo C; Riccardi C; Celentano M; Mele G
    Am J Hematol; 2010 Sep; 85(9):687-90. PubMed ID: 20652967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative real-time RT-PCR detects elevated Wilms tumor gene (WT1) expression in autologous blood stem cell preparations (PBSCs) from acute myeloid leukemia (AML) patients indicating contamination with leukemic blasts.
    Siehl JM; Thiel E; Leben R; Reinwald M; Knauf W; Menssen HD
    Bone Marrow Transplant; 2002 Mar; 29(5):379-81. PubMed ID: 11919726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.